Alloplex Biotherapeutics Inc. announced the formation of a Corporate Board today: at a pivotal juncture in the organization’s development as it is poised to embark on its first-in-human clinical trial.

The inaugural members of the Board are Dr. Sung-Wuk Kim and Mr. TaeOh ‘Jared’ Chung.

• Dr. Sung-Wuk Kim, DDS has spent over a decade at the helm of drug development programs including those for autoimmune diseases, fibrosis and metabolic diseases. He has obtained more than 30 patents in formulation, biologics and small molecule drugs and pioneered the OXPHOS inhibitor research platform designed to target cancer metabolism, var, which produced ImmunoMet’s lead drug candidate, IM156.

• Jared T. Chung, B.Sc (BME) is a co-founder and key member of the investment team at Clairvoyant Ventures. In his previous capacity at Daesung Private Equity he managed venture capital and start-up investment with a biotech and energy focus. Jared’s unbiased evaluation of Alloplex resulted in a significant investment by Clairvoyant which assured the necessary resources for Alloplex to advance into the clinical stage.

Commenting on Dr. Kim’s appointment, Alloplex’s Scientific Founder and CEO, Dr. Frank Borriello MD PhD said, “My connection with Dr. Kim dates back to the early days of Alloplex when Sung made the first outside investment to Alloplex. His financial support and generous intellectual contribution has been integral to the organization’s ability to advance to the clinic in a record time of just over 5 years. There’s no doubt that he is an enthusiastic luminary in our field who is willing to tolerate risk in advancing promising assets. His exceptional track record will be a strong strategic asset to our Board.”

Dr. Kim said, “I have been impressed with scientific rigour and highly-differentiated approach of Alloplex and its SUPLEXA therapeutic cells. I am pleased to add my insights, knowledge of the Korean biotech sector and commitment to excellence to the Board to support the organization’s advancement.”

Commenting on Jared Chung’s appointment Dr. Borriello said, “Jared brings his independent perspective and proficiency in deal sourcing and fund raising to the Alloplex Board. His oversight will be immensely valuable as we execute our lead clinical cellular therapy program and seek investment and collaboration opportunities in Asia and other markets.”

“I have great confidence in the potential of Alloplex Biotherapeutics, Inc.,” Mr. Chung said, “I look forward to adding my expertise in value-creation to the Board to support Frank and his leadership team at this important time.”

---

About Alloplex:

Alloplex Biotherapeutics, Inc., a private biotechnology company. Alloplex has developed a highly-differentiated, non-engineered cellular therapy platform with broad anti-tumor activity. Preclinical in vitro and animal model data indicate that the platform is applicable across multiple tumor types.

Alloplex’s manufacturing planning is well-advanced. Its first in-human clinical trials are slated to commence in 1Q 2022.